Lunsekimig (SAR443765) is an anti-TSLP/IL13/ALB nonobody composed of 5 sequentially linked variable region heavy chains. Lunsekimig decreases blood eosinophils and lowers plasma levels of IL-5, eotaxin-3, and IgE. Lunsekimig also improves lung function. Lunsekimig can be used for the study and treatment of type 2 inflammatory asthma[1][2].
Molecular Weight:
(69.702 kDa)
Purity:
98.00
CAS Number:
[2770858-49-4]
Target:
Interleukin Related
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
